Q2 2024
Released Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0001493152-24-030648
Q2 2024 · 10-Q
Revenue$89.57K$89.57K — vs Q2 2023−98.8% vs Q1 2024
Net Income-$3.07M-$3.07M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.56-$0.56 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$3,292,568N/M
Operating Cash Flowderived-$2,497,777N/M
Margins · derived
Operating margin-3676.2%
Net margin-3426.2%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $89.57K | $0.00 | $500.00K | — |
| Net Income | -$3.07M | -$3.55M | -$2.63M | -$6.81M |
| EPS Diluted | -$0.56 | -$0.68 | -$0.61 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR